2020
DOI: 10.1016/j.neuropharm.2019.107850
|View full text |Cite
|
Sign up to set email alerts
|

Chitosan nanoparticles release nimodipine in response to tissue acidosis to attenuate spreading depolarization evoked during forebrain ischemia

Abstract: Tissue acidosis with cerebral ischemia was exploited for controlled drug release. • Nimodipine release from nanoparticles to low pH was shown in ischemic brain tissue. • Nimodipine delivered by nanoparticles improved perfusion in ischemic brain tissue. • Nimodipine delivered by nanoparticles inhibited spreading depolarization. • The applied chitosan nanoparticles did not activate microglia in the brain.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
16
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 32 publications
(16 citation statements)
references
References 61 publications
0
16
0
Order By: Relevance
“…Tissue that leads to an equilibrium or recovery in pH could predict overall tissue recovery. Also, the acidosis in ischemic tissue has been recently utilized for therapeutic strategies, with acidosis-responsive nanoparticles being able to release neuroprotectants (Tóth et al, 2020b). Understanding the temporal dynamics of pH change post-stroke will enable improved therapeutic targeting in the right location and time window for ischemic stroke.…”
Section: Discussionmentioning
confidence: 99%
“…Tissue that leads to an equilibrium or recovery in pH could predict overall tissue recovery. Also, the acidosis in ischemic tissue has been recently utilized for therapeutic strategies, with acidosis-responsive nanoparticles being able to release neuroprotectants (Tóth et al, 2020b). Understanding the temporal dynamics of pH change post-stroke will enable improved therapeutic targeting in the right location and time window for ischemic stroke.…”
Section: Discussionmentioning
confidence: 99%
“…The nanocarrier synthesized in this study was a pH-sensitive drug delivery system. To detect SAG release behavior in vitro, the SAG@HES and SAG@PHSRN-HES were dissolved in sterile PBS at pH 6.7 (simulating the acidic environment of ischemic tissue) and pH 7.4 (simulating physiological conditions such as normal tissue and blood circulation) and released for 48 h. [25,30] As the pH value decreased, the SAG release rate of the nanocarrier system increased (Figure 2A,B). The SAG release of SAG@HES in PBS at pH 7.4 and 6.7 was 54.12% and 63.64% in 8 h, respectively.…”
Section: In Vitro and In Vivo Drug Releasementioning
confidence: 99%
“…74,75 Nimodipine, another CCB known for its selectivity for cerebral vascular district, in spite of its lipophilicity, when encapsulated in CS NPs benefits of a better delivery. 76 These are just examples of how, besides working on new CCBs molecules, a novel therapeutic strategy may involve the encapsulation of already known CCBs in appropriately functionalized NPs to improve the bioavailability and to limit the pleiotropic effects that especially dihydropyridines manifest.…”
Section: Reducing Intracellular Calciummentioning
confidence: 99%